Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Trial Profile

Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Unoprostone (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors R-Tech Ueno
  • Most Recent Events

    • 28 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2015 Based on top-line data from this trial, Sucampo has decided not to continue development of unoprostone and will return all licenses to R-Tech Ueno, according to a media release.
    • 09 Mar 2015 Preliminary top-line results published in R-Tech Ueno media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top